Literature DB >> 30243570

Prognostic Nomogram for Overall Survival in Extranodal Natural Killer/T-Cell Lymphoma Patients.

Kaiguo Li1, Ruyue Wang2, Shiting Huang1, Xinbin Pan1, Hongmin Chen1, Lei Zhou1, Junbao Wei1, Chunhua Wu1, Xiaodong Zhu1, Shixiong Liang1, Song Qu3.   

Abstract

BACKGROUND: Extranodal natural killer/T-cell lymphoma (ENKTL) is a rare lymphoid malignancy with diverse clinical features and prognoses. The aims of this study were to explore the pretreatment prognostic factors of ENKTL and develop a new individual prognostic model. PATIENTS AND METHODS: We retrospectively enrolled 81 ENKTL patients with newly diagnosed disease between June 2006 and August 2017 at the Affiliated Cancer Hospital of Guangxi Medical University. Survival analysis was used to assess the prognostic value of various factors. A nomogram was developed to predict overall survival (OS) based on the Cox proportional hazards model.
RESULTS: The median survival time of the patients was 48 months, and the 5-year OS rate was 47.5%. Cox regression analysis showed that the prognostic factors of OS for ENKTL patients included Eastern Cooperative Oncology Group performance status, Ann Arbor stage, pretreatment albumin-to-globulin ratio, and platelet count. A prognostic nomogram was developed to predict the OS rate for ENKTL patients based on these factors. The calibration curve showed that the nomogram was able to predict OS accurately. The concordance index of the nomogram for OS prediction was 0.807.
CONCLUSION: Our proposed nomogram based on Eastern Cooperative Oncology Group performance status, Ann Arbor stage, albumin-to-globulin ratio, and platelet count provides an individualized risk estimate of OS in patients with ENKTL.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Albumin-to-globulin ratio; Calibration curve; Lymphoid malignancy; Platelet count; Prognostic model

Mesh:

Substances:

Year:  2018        PMID: 30243570     DOI: 10.1016/j.clml.2018.08.011

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  5 in total

1.  Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma.

Authors:  Zhenjie Qu; Tingting Zhang; Fenghua Gao; Wenchen Gong; Yaoli Cui; Lihua Qiu; Zhengzi Qian; Shiyong Zhou; Bin Meng; Xiubao Ren; Lanfang Li; Xianhuo Wang; Huilai Zhang
Journal:  Biomed Res Int       Date:  2022-05-24       Impact factor: 3.246

2.  Prognostic value of the albumin-globulin ratio and albumin-globulin score in patients with multiple myeloma.

Authors:  Ying Cai; Yu Zhao; Qiuxin Dai; Maozhong Xu; Xin Xu; Wenkai Xia
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

3.  Development and External Validation of a Nomogram to Predict Cancer-Specific Survival in Patients with Primary Intestinal Non-Hodgkin Lymphomas.

Authors:  Cuifen Zhang; Zeyu Liu; Jiahao Tao; Lizhu Lin; Linzhu Zhai
Journal:  Cancer Manag Res       Date:  2021-12-20       Impact factor: 3.989

4.  Nomogram for perinatal prediction of intrapartum fever: a retrospective case-control study.

Authors:  Zhenfei Jiang; Xiaoyi Hu; Huabei Zeng; Xinghe Wang; Cheng Tan; Chunyan Ni; Lingyun Dai; Su Liu
Journal:  BMC Pregnancy Childbirth       Date:  2021-06-25       Impact factor: 3.007

5.  High C-Reactive Protein to Albumin Ratio Predicts Inferior Clinical Outcomes in Extranodal Natural Killer T-Cell Lymphoma.

Authors:  Quan-Shu Di; Tao Xu; Ying Song; Zhi-Gang Zuo; Feng-Jun Cao; Xiong-Jie Yu; Ji-Ying Tang; Wei Zhang; Chen Li; Guo-Xing Wan; Xiao-Jun Cai
Journal:  Dose Response       Date:  2020-04-07       Impact factor: 2.658

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.